Caris Life Sciences (NASDAQ: CAI) has introduced a multimodal, AI‑powered “immunotherapy treatment selection” signature for a subset of non‑small cell lung cancer (NSCLC) patients who are…
Shares of Sleep Number Corporation (Nasdaq: SNBR) are bouncing hard, up about 36%, as traders cover shorts and bottom‑fish a name that has been pricing in severe…
Plus Therapeutics, Inc. (NASDAQ: PSTV) recently announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead radiotherapeutic. This milestone…
A DoW Partnership Puts AI-Powered EEG Inside Military PTSD and TBI Programs Firefly Neuroscience (Nasdaq: AIFF) is moving into defense healthcare. On March 26, 2026,…
Artivion, Inc. (NYSE: AORT) has received U.S. FDA approval for the NEXUS Aortic Arch System, the first off‑the‑shelf branched endovascular stent graft specifically designed to treat aortic arch…
April 06, 2026
ImmunityBio Shares Rebound as Company Moves to Resolve FDA Warning on Anktiva Promotion
ImmunityBio Inc. (NASDAQ: IBRX) is bouncing back after previously sliding 20–27% on news that the FDA’s Office of Prescription Drug Promotion issued a warning letter over…
April 02, 2026
BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in Ischemic Heart Failure
BioCardia, Inc. (NASDAQ: BCDA) has submitted full CardiAMP Heart Failure clinical data to the U.S. Food and Drug Administration and requested a meeting this quarter…
Shares of Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) are surging again, recently up about 60% as traders continue to pile into the ultra‑low‑float AI‑driven drug‑development name following…
Boston Scientific (NYSE: BSX) reported new CHAMPION‑AF data at ACC.26 showing its WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and…
United Therapeutics Corporation (NASDAQ:UTHR) saw its shares jump 12% on Monday, following the announcement of promising results from its TETON-1 pivotal study of Tyvaso. The…
Shares of Polaryx Therapeutics, Inc. (NASDAQ: PLYX) are up roughly 22% as investors rotate into high‑beta, low‑float biotech names leveraged to rare‑disease upside. The move reflects heightened…
March 27, 2026
AstraZeneca’s IL‑33 Drug Delivers Big COPD Win
AstraZeneca’s (NYSE: AZN) tozorakimab just delivered Phase III COPD data that can move the needle on a major respiratory asset, showing clinically meaningful exacerbation reductions…